Ferric carboxymaltose vs Ferric derisomaltose

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Iron repletion · full Heart Failure pipeline

Ferric carboxymaltose · Injectafer / Ferinject

Marketed by Daiichi Sankyo and partners

Approved in Heart FailureIron complex (IV)
Partial signal

NCT03037931 · Phase 3 · completed

This double-blind, randomized, placebo-controlled trial (HEART-FID) assigned 3,065 ambulatory patients with heart failure, an ejection fraction of 40% or less and iron deficiency to ferric carboxymaltose or placebo. The primary outcome was one hierarchical composite of death, heart failure hospitalization and 6-minute walk distance, tested at a significance level of 0.01. The win ratio was 1.10 (99% CI 0.99 to 1.23, P=0.02), which did not reach that level, and the authors report no apparent difference between the groups, so the primary endpoint was missed. The figures come from the peer-reviewed primary report (Mentz et al., N Engl J Med 2023).

Next expected readout: December 2026 · NCT05793996 (registry estimate)

Reported efficacy

Number of Deaths (1 year); Number of Hospitalizations for Heart Failure (1 year); Change in 6MWT (Six Minute Walk Test) Distance (6 months): Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. (missed)

Result source: NCT03037931

Ferric derisomaltose · Monoferric / Monofer

Marketed by Pharmacosmos and partners

Phase 3 in Heart FailureIron complex (IV)
Weak signal

NCT00537186 · Phase 3 · completed

This was a small, open-label, single-arm study of intravenous iron isomaltoside in patients with chronic heart failure and iron deficiency anaemia who needed parenteral iron. It had no comparison group, and all of its primary outcomes were safety measures, so there is no primary comparison that can be met or missed. A published pilot study with the same sponsor, design and size (20 patients) reported no treatment-related adverse reactions over 8 weeks. Results were not posted on ClinicalTrials.gov.

Next expected readout: August 2027 · NCT06427343 (registry estimate)

Reported efficacy

Adverse events (AE) (Number and type of AE) (Eight weeks after enrollment); Serious adverse events (SAEs) (Eight weeks after enrollment); Physical examination (At screening visit and at end of study); Vital signs (At every visit); Clinical laboratory tests (biochemistry, haematology) (At every visit): Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks. (not_applicable)

Result source: NCT00537186

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFerric carboxymaltoseFerric derisomaltose
CV death or HF hospitalisation—Not posted · NCT03833336—Not posted · NCT04945707
HF hospitalisation25.4% vs 32.4%−7 vs placebowk 52 · n 558NCT02937454—Not posted · NCT04945707
CV death—Not posted · NCT03833336—Not posted · NCT04945707
KCCQ clinical summary, change—Not posted · NCT03833336—Not posted · NCT04945707

CV death or HF hospitalisation

Ferric carboxymaltose
—Not posted · NCT03833336
Ferric derisomaltose
—Not posted · NCT04945707

HF hospitalisation

Ferric carboxymaltose
25.4% vs 32.4%−7 vs placebowk 52 · n 558NCT02937454
Ferric derisomaltose
—Not posted · NCT04945707

CV death

Ferric carboxymaltose
—Not posted · NCT03833336
Ferric derisomaltose
—Not posted · NCT04945707

KCCQ clinical summary, change

Ferric carboxymaltose
—Not posted · NCT03833336
Ferric derisomaltose
—Not posted · NCT04945707
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ferric derisomaltose
Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks. NCT00537186 · Phase 3 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ferric carboxymaltose: 4 of 4 rows · Ferric derisomaltose: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFerric carboxymaltose
Dropout rate
26.7%a
NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3
show 2 more results
24.7%FCM (Ferric Carboxymaltose)
NCT02937454 · Phase 4 · registry result, not featured evidence
—Group 1 - FCM (Ferric Carboxymalto
NCT02937454 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3
show 2 more results
0%FCM (Ferric Carboxymaltose)
NCT02937454 · Phase 4 · registry result, not featured evidence
—Group 1 - FCM (Ferric Carboxymalto
NCT02937454 · Phase 4 · registry result, not featured evidence
Serious AEs
27%a
NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3
show 2 more results
—FCM (Ferric Carboxymaltose)
NCT02937454 · Phase 4 · registry result, not featured evidence
44.7%Group 1 - FCM (Ferric Carboxymalto
NCT02937454 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
pneumonia 3.7% (placebo 2.3%)
cardiac disorders 3.3% (placebo 3.4%)
acute kidney injury 3% (placebo 2.6%)
NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3
show 1 more result
cardiac failure 9.1% (placebo 8.2%)
NCT02937454 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ferric carboxymaltose

6MWD - Change 8.179 vs 3.979 placebo m @ 26wk
absolute change · m
NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3
CV Death or CV Hospitalization Total 370 vs 451 placebo count @ 52wk
event count · count
Full Analysis Set (FAS)
NCT02937454 · Phase 4 · registry result, not featured evidence
HF Hospitalization 25.4% (n=558) vs 32.4% (n=550) placebo @ 52wk
responder rate · % of participants
NCT02937454 · Phase 4 · registry result, not featured evidence · converted to % from 142 Participants as posted
CV Hospitalization 32.4% (n=558) vs 40% (n=550) placebo @ 52wk
event count · % of participants
NCT02937454 · Phase 4 · registry result, not featured evidence · converted to % from 181 Participants as posted
EQ-5D-5L Index 0.05 vs 0.03 placebo Change from baseline in EQ-5D-5L @ 6wk
absolute change · Change from baseline in EQ-5D-5L
NCT02937454 · Phase 4 · registry result, not featured evidence
show 2 more results
0.06 vs 0.05 placebo Change from baseline in EQ-5D-5L @ 24wk
NCT02937454 · Phase 4 · registry result, not featured evidence
0.06 vs 0.06 placebo Change from baseline in EQ-5D-5L @ 52wk
NCT02937454 · Phase 4 · registry result, not featured evidence
KCCQ-12 18.53 vs 17.24 placebo score @ 2wk
absolute value · score
NCT02937454 · Phase 4 · registry result, not featured evidence
show 6 more results
21.26 vs 18.36 placebo score @ 4wk
NCT02937454 · Phase 4 · registry result, not featured evidence
23.49 vs 19.88 placebo score @ 6wk
NCT02937454 · Phase 4 · registry result, not featured evidence
25.57 vs 21.88 placebo score @ 12wk
NCT02937454 · Phase 4 · registry result, not featured evidence
26.3 vs 23.32 placebo score @ 24wk
NCT02937454 · Phase 4 · registry result, not featured evidence
25.78 vs 23.7 placebo score @ 36wk
NCT02937454 · Phase 4 · registry result, not featured evidence
25.75 vs 24.31 placebo score @ 52wk
NCT02937454 · Phase 4 · registry result, not featured evidence

Chronic Kidney Disease

Shared mechanism: Iron repletion · full Chronic Kidney Disease pipeline

Ferric carboxymaltose · Injectafer / Ferinject

Marketed by Daiichi Sankyo and partners

Approved in Chronic Kidney DiseaseIron complex (IV)
Partial signal

NCT00317239 · Phase 3 · completed

The study randomized 255 participants to ferric carboxymaltose or active oral iron treatment, but it was open-label rather than blinded. Its primary endpoint was a surrogate hemoglobin response measure, and although the reported counts favored ferric carboxymaltose, statistical significance is not reported, so the result cannot be considered definitively met.

Reported efficacy

Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101 (unclear)

Result source: NCT00317239

Ferric derisomaltose · Monoferric / Monofer

Marketed by Pharmacosmos and partners

Approved in Chronic Kidney DiseaseIron complex (IV)
Partial signal

NCT02940860 · Phase 3 · completed

This was a large (n=1538), randomized, open-label, active-controlled Phase 3 trial of ferric derisomaltose versus iron sucrose in non-dialysis-dependent chronic kidney disease with iron deficiency anemia. The primary efficacy endpoint — change in hemoglobin from baseline to week 8 — met its prespecified non-inferiority margin (difference 0.08 g/dL; 95% CI -0.06 to 0.23, lower bound above -0.5 g/dL), and the co-primary safety endpoint of serious or severe hypersensitivity reactions was low in the ferric derisomaltose arm (3/1019, 95% CI upper bound 0.86%, below the 3% threshold). Although the trial was adequately powered with a hard clinical endpoint, it was open-label rather than double-blind, which is a meaningful design limitation.

Reported efficacy

Change in Hemoglobin (Hb) From Baseline to Week 8; Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions (Baseline to week 8): Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26) (met)

Result source: NCT02940860

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFerric carboxymaltoseFerric derisomaltose
Kidney composite outcome—Not reported—Not posted · NCT00536666
UACR, % change—Not reported—Not posted · NCT00536666
eGFR slope—Not reported—Not posted · NCT00536666
Haemoglobin, change—Not reported1.2 vs 1.1vs Iron Sucrosewk 8 · n 1027NCT02940860
6 other results
  • 0.6 vs 0.3 wk 4 · n 209 · Phase 3 · primary NCT01102413
  • 1.1 vs 0.9 wk 4 · n 1027 · Phase 3 · secondary NCT02940860
  • 0.8 vs 0.5 wk 2 · n 1027 · Phase 3 · secondary NCT02940860
  • 0.4 vs 0.2 wk 1 · n 1027 · Phase 3 · secondary NCT02940860
  • 0.9 vs 0.5 wk 8 · n 210 · Phase 3 · secondary NCT01102413
  • -0.1 vs -0.1 wk 6 · n 216 · Phase 3 · secondary NCT01222884

Kidney composite outcome

Ferric carboxymaltose
—Not reported
Ferric derisomaltose
—Not posted · NCT00536666

UACR, % change

Ferric carboxymaltose
—Not reported
Ferric derisomaltose
—Not posted · NCT00536666

eGFR slope

Ferric carboxymaltose
—Not reported
Ferric derisomaltose
—Not posted · NCT00536666

Haemoglobin, change

Ferric carboxymaltose
—Not reported
Ferric derisomaltose
1.2 vs 1.1vs Iron Sucrosewk 8 · n 1027NCT02940860
6 other results
  • 0.6 vs 0.3 wk 4 · n 209 · Phase 3 · primary NCT01102413
  • 1.1 vs 0.9 wk 4 · n 1027 · Phase 3 · secondary NCT02940860
  • 0.8 vs 0.5 wk 2 · n 1027 · Phase 3 · secondary NCT02940860
  • 0.4 vs 0.2 wk 1 · n 1027 · Phase 3 · secondary NCT02940860
  • 0.9 vs 0.5 wk 8 · n 210 · Phase 3 · secondary NCT01102413
  • -0.1 vs -0.1 wk 6 · n 216 · Phase 3 · secondary NCT01222884
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Ferric carboxymaltose: 4 of 5 rows · Ferric derisomaltose: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFerric carboxymaltoseFerric derisomaltose
Hemoglobin Increase 1g/dL
event count · % of participants
60.4% (n=144) vs 34.7% (n=101) Ferrous Sulfate Tablets*a,b,c
NCT00317239 · Phase 3 · monotherapy · converted to % from 87 participants as posted
46.2% (n=1027) vs 44.2% (n=511) Iron Sucrose @ 8wk*a,b,c
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 474 Participants as posted
Dropout rate
8.8%d
NCT00317239 · Phase 3 · monotherapy
show 4 more results
14.2%FCM (High Ferritin Target)
NCT00994318 · Phase 3 · registry result, not featured evidence
11.7%FCM (Low Ferritin Target)
NCT00994318 · Phase 3 · registry result, not featured evidence
2.7%
NCT00548691 · Phase 3 · registry result, not featured evidence
18.1%
NCT00317226 · Phase 3 · registry result, not featured evidence
5.5%e
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 2 more results
10.7%
NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
10.3%
NCT01222884 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—d
NCT00317239 · Phase 3 · monotherapy
show 4 more results
—FCM (High Ferritin Target)
NCT00994318 · Phase 3 · registry result, not featured evidence
—FCM (Low Ferritin Target)
NCT00994318 · Phase 3 · registry result, not featured evidence
—
NCT00548691 · Phase 3 · registry result, not featured evidence
—
NCT00317226 · Phase 3 · registry result, not featured evidence
—e
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 2 more results
—
NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
—
NCT01222884 · Phase 3 · registry result, not featured evidence
Serious AEs
8.8%d
NCT00317239 · Phase 3 · monotherapy
show 4 more results
25.3%FCM (High Ferritin Target)
NCT00994318 · Phase 3 · registry result, not featured evidence
24%FCM (Low Ferritin Target)
NCT00994318 · Phase 3 · registry result, not featured evidence
4.3%
NCT00548691 · Phase 3 · registry result, not featured evidence
18.1%
NCT00317226 · Phase 3 · registry result, not featured evidence
8.1%e
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 2 more results
5.3%
NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
9.6%
NCT01222884 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
d
odema peripheral 6.1%
constipation 1.4%
NCT00317239 · Phase 3 · monotherapy
show 3 more results
hypertension 13.6%
oedema peripheral 13.6%
urinary tract infection 11.7%
NCT00994318 · Phase 3 · registry result, not featured evidence
oedema peripheral 14%
hypertension 9.3%
back pain 8%
NCT00994318 · Phase 3 · registry result, not featured evidence
odema peripheral 7.1%
hypertension 5.5%
urinary tract infection 5.5%
NCT00317226 · Phase 3 · registry result, not featured evidence
e
hyperkalaemia 2.2%
urinary tract infection 2.2%
hypertension 1.4%
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 2 more results
nasopharyngitis 3.1%
pyrexia 3.1%
diarrhoea 2.6%
NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
fall 3%
headache 3%
c-reactive protein increased 2.6%
NCT01222884 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation context differs: registered conditions differ.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ferric carboxymaltose

Time to Other Anemia Therapy or Hb Trigger 23.5% (n=153) vs 31.8% (n=308) Oral Iron @ 52wk
event count · % of participants
Number of patients with events
NCT00994318 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
show 1 more result
32.2% (n=152) vs 31.8% (n=308) Oral Iron @ 52wk*
Number of patients with events
NCT00994318 · Phase 3 · registry result, not featured evidence · converted to % from 49 participants as posted

Ferric derisomaltose

Hemoglobin Change g/dL 1.22 vs 1.14 Iron Sucrose g/dL @ 8wk
absolute change · g/dL
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 6 more results
0.44 vs 0.21 Iron Sucrose g/dL @ 1wk
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
0.77 vs 0.5 Iron Sucrose g/dL @ 2wk
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
1.08 vs 0.9 Iron Sucrose g/dL @ 4wk
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
0.57 vs 0.35 Iron Sulphate g/dL @ 4wk
NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
0.92 vs 0.45 Iron Sulphate g/dL @ 8wk
NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
-0.07 vs -0.06 Iron Sucrose g/dL @ 6wk
NCT01222884 · Phase 3 · registry result, not featured evidence
Time to Hemoglobin Increase 1g/dL 1.84 vs 1.84 Iron Sucrose months
time to event · months
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to months from 56 days as posted
Hemoglobin Above 12g/dL 25.2% (n=1027) vs 23.7% (n=510) Iron Sucrose
event count · % of participants
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 259 Participants as posted
Hemoglobin Increase 2 g/dL 29.9% (n=1027) vs 26.1% (n=510) Iron Sucrose
event count · % of participants
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 307 Participants as posted
Hemoglobin 82.7% (n=226) vs 82.6% (n=115) Iron Sucrose @ 6wk
responder rate · % of participants
NCT01222884 · Phase 3 · registry result, not featured evidence

Iron Deficiency Anemia

Shared mechanism: Iron repletion · full Iron Deficiency Anemia pipeline

Ferric carboxymaltose · Injectafer / Ferinject

Marketed by Daiichi Sankyo and partners

Approved in Iron Deficiency AnemiaIron complex (IV)
Partial signal

NCT00982007 · Phase 3 · completed

This open-label randomized trial enrolled 997 people with iron deficiency anemia in two cohorts: those who did not respond to oral iron were compared with oral ferrous sulfate, and others with intravenous standard-of-care iron. The primary endpoint was the rise to the highest hemoglobin by day 35. Ferric carboxymaltose raised hemoglobin more than the comparator in both cohorts (1.57 vs 0.80 g/dL and 2.90 vs 2.16 g/dL, p=0.001), so the primary endpoint was met. The figures come from the registry results and the sponsor's approval release.

Next expected readout: September 2027 · NCT06061393 (registry estimate)

Reported efficacy

Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study. (Day 56); Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population. (Day 120): Primary efficacy endpoint, mean change to highest hemoglobin from baseline to day 56: ferric carboxymaltose 1.13 g/dL (n=1,249) vs iron sucrose 0.92 g/dL (n=1,244); treatment difference 0.21 g/dL (95% CI 0.13 to 0.28), statistically significant. Primary composite cardiovascular safety endpoint: 13.71% vs 12.14% (difference 1.57%, 95% CI -1.10% to 4.25%), no significant difference. (met)

Result source: NCT00981045

Ferric derisomaltose · Monoferric / Monofer

Marketed by Pharmacosmos and partners

Approved in Iron Deficiency AnemiaIron complex (IV)
Partial signal

NCT02940860 · Phase 3 · completed

This was a large (n=1538), randomized, open-label, active-controlled Phase 3 trial of ferric derisomaltose versus iron sucrose in non-dialysis-dependent chronic kidney disease with iron deficiency anemia. The primary efficacy endpoint — change in hemoglobin from baseline to week 8 — met its prespecified non-inferiority margin (difference 0.08 g/dL; 95% CI -0.06 to 0.23, lower bound above -0.5 g/dL), and the co-primary safety endpoint of serious or severe hypersensitivity reactions was low in the ferric derisomaltose arm (3/1019, 95% CI upper bound 0.86%, below the 3% threshold). Although the trial was adequately powered with a hard clinical endpoint, it was open-label rather than double-blind, which is a meaningful design limitation.

Next expected readout: November 2026 · NCT04913649 (registry estimate)

Reported efficacy

Change in Hemoglobin (Hb) From Baseline to Week 8; Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions (Baseline to week 8): Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26) (met)

Result source: NCT02940860

Results for Iron Deficiency Anemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ferric carboxymaltose
Primary endpoint, mean increase to highest hemoglobin from baseline to day 35: Cohort 1, ferric carboxymaltose 1.57 g/dL (n=244) vs oral ferrous sulfate 0.80 g/dL (n=251); Cohort 2, ferric carboxymaltose 2.90 g/dL (n=245) vs IV standard of care 2.16 g/dL (n=237); both differences statistically significant (p=0.001). NCT00982007 · Phase 3 · design grade: moderate · publication or press release
Primary efficacy endpoint, mean change to highest hemoglobin from baseline to day 56: ferric carboxymaltose 1.13 g/dL (n=1,249) vs iron sucrose 0.92 g/dL (n=1,244); treatment difference 0.21 g/dL (95% CI 0.13 to 0.28), statistically significant. Primary composite cardiovascular safety endpoint: 13.71% vs 12.14% (difference 1.57%, 95% CI -1.10% to 4.25%), no significant difference. NCT00981045 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Ferric carboxymaltose: 2 of 4 rows · Ferric derisomaltose: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFerric carboxymaltoseFerric derisomaltose
Dropout rate
2.7%a
NCT00548691 · Phase 3 · registry result, not featured evidence
5.5%b
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 1 more result
8.7%
NCT02962648 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00548691 · Phase 3 · registry result, not featured evidence
—b
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 1 more result
—
NCT02962648 · Phase 3 · registry result, not featured evidence
Serious AEs
4.3%a
NCT00548691 · Phase 3 · registry result, not featured evidence
8.1%b
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 1 more result
12.7%
NCT02962648 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs—
b
hyperkalaemia 2.2%
urinary tract infection 2.2%
hypertension 1.4%
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 1 more result
abdominal pain 2.9%
anaemia 2.9%
dizziness 2.9%
NCT02962648 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ferric derisomaltose

Hemoglobin Change g/dL 1.22 vs 1.14 Iron Sucrose g/dL @ 8wk
absolute change · g/dL
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
show 3 more results
0.44 vs 0.21 Iron Sucrose g/dL @ 1wk
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
0.77 vs 0.5 Iron Sucrose g/dL @ 2wk
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
1.08 vs 0.9 Iron Sucrose g/dL @ 4wk
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3
Hemoglobin Increase 1g/dL 19.5% (n=1027) vs 15.3% (n=511) Iron Sucrose @ 1wk
event count · % of participants
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 200 Participants as posted
show 3 more results
33% (n=1027) vs 21.9% (n=511) Iron Sucrose @ 2wk*
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 339 Participants as posted
41.9% (n=1027) vs 34.1% (n=511) Iron Sucrose @ 4wk*
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 430 Participants as posted
46.2% (n=1027) vs 44.2% (n=511) Iron Sucrose @ 8wk*
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 474 Participants as posted
Time to Hemoglobin Increase 1g/dL 1.84 vs 1.84 Iron Sucrose months
time to event · months
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to months from 56 days as posted
Hemoglobin Above 12g/dL 25.2% (n=1027) vs 23.7% (n=510) Iron Sucrose
event count · % of participants
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 259 Participants as posted
Hemoglobin Increase 2 g/dL 29.9% (n=1027) vs 26.1% (n=510) Iron Sucrose
event count · % of participants
NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 307 Participants as posted
Hemoglobin Change g/dL 1.23 g/dL @ 2wk
absolute change · g/dL
No placebo or comparator arm
NCT02962648 · Phase 3 · registry result, not featured evidence
show 2 more results
1.73 g/dL @ 13wk
NCT02962648 · Phase 3 · registry result, not featured evidence
1.34 g/dL @ 26wk
NCT02962648 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ferric carboxymaltose's landscape · Ferric derisomaltose's landscape